US FDA hits Indoco with warning due to leaky glaucoma drug

By Dan Stanton contact

- Last updated on GMT

Image: iStock/aga7ta
Image: iStock/aga7ta

Related tags: Fda warning letter, Food and drug administration

Leakage problems for of an ophthalmic drug has landed contract manufacturer Indoco Remedies with a US FDA warning letter at its plant in Goa.

In September​, Indian API and finished formulation maker Indoco Remedies received a Form 483 with six observations following an inspection by the US Food and Drug Administration (FDA) at its Goa II facility.

“We submitted our comments to FDA in November 2016 and were eagerly awaiting for the EIR [Establishment Inspection Report],”​ MD Sundeep Bambolkar said during a conference call Monday.

“Based on the review of compliance, FDA has accepted our response to five observations. However, the FDA remains concerned with one observation pertaining to a specific product for which Indoco is a contract manufacturer [and] on Friday 31 March we received a warning letter from FDA.”

The observation relates only to latanoprost ophthalmic solution – a generic version of Pfizer’s Xalatan – which Indoco makes for a US partner. The contract generates revenue of around INR250m ($3.8m) for Indoco each year.

According to Bambolkar the FDA has concerns about the potential of leakage of the product during shipping and issues with the level of communication Indoco has with its US partner.

He added despite the warning, the FDA has not issued an import alert and Indoco is free to continue to supply this and other products from the Goa plant.

“As for US FDA recommendations we are in the process of appointing a cGMP consultant and we shall respond to the warning letter within the stipulated time of 15 days. We will continue to supply the existing product from the aforementioned facility to meet our obligations to our customers and the patients in the USA.”

During the call, Indoco did not reveal its US partner but it is fully aware of the problem.

Related news

Related products

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Why Blister Packaging: Things to Consider

Why Blister Packaging: Things to Consider

Catalent Pharma Solutions | 03-Dec-2020 | Insight Guide

The decision to use blister packaging for either clinical trials or commercial drug manufacturing comes with a host of factors to consider. Pharmaceutical...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Related suppliers

Follow us


View more